Monday, May 27, 2024

Research Strengthens Case for Treating COVID-19 with Metformin Over Ivermectin, Study Finds

New research from the University of Minnesota suggests that COVID-19 patients treated with metformin show lower viral loads, advocating for broader use of the affordable anti-diabetes drug over the controversial ivermectin.

The University of Minnesota’s latest research reveals that COVID-19 patients treated with metformin exhibited lower viral loads compared to those who didn’t receive the medication. This finding supports the use of metformin as a potential treatment for COVID-19 and discourages the use of ivermectin, a drug mired in controversy.

The study, led by Dr. Carolyn Bramante, demonstrates a significant reduction in the amount of virus present in patients who took metformin, compared to those who received a placebo. The research also indicates that metformin users were less likely to experience a rebound in viral loads after ten days, suggesting a lower risk of post-COVID complications, such as long COVID.

While metformin showed promising results in reducing viral loads, ivermectin and fluvoxamine, two other drugs considered for COVID-19 treatment, did not exhibit statistically significant benefits in the University of Minnesota-led trial.

Metformin’s efficacy was observed not only in unvaccinated participants but also in vaccinated individuals. Moreover, it proved effective against various coronavirus variants, including alpha, delta, and omicron, which have caused distinct waves of COVID-19 over the past three years.

Despite a decline in COVID-19-related hospitalizations and deaths, the threat of long COVID persists. Recent federal survey data indicates that more than 7% of Minnesota adults are still grappling with the lingering effects of the virus.

In response to ongoing concerns, federal health officials have urged individuals aged 65 and older, who are at the greatest risk of severe COVID-19, to seek additional vaccine boosters. However, uptake among seniors remains slow, with only 3% reported as up to date on COVID vaccinations according to the latest state data.

Related Articles

Latest Articles

Most Popular